Forming next-generation antibody–nanoparticle conjugates through the oriented installation of non-engineered antibody fragments† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c7sc02747h

Enabling oriented installation of non-engineered antibody fragments on nanoparticle surfaces to create next-generation antibody–nanoparticle conjugates.

[1]  N. Nishiyama,et al.  Antibody fragment-conjugated polymeric micelles incorporating platinum drugs for targeted therapy of pancreatic cancer. , 2015, Biomaterials.

[2]  R. Kontermann,et al.  Bispecific single-chain diabody-immunoliposomes targeting endoglin (CD105) and fibroblast activation protein (FAP) simultaneously. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[3]  Igor L. Medintz,et al.  Functionalizing nanoparticles with biological molecules: developing chemistries that facilitate nanotechnology. , 2013, Chemical reviews.

[4]  Rachel S. Riley,et al.  Frizzled7 Antibody-Functionalized Nanoshells Enable Multivalent Binding for Wnt Signaling Inhibition in Triple Negative Breast Cancer Cells. , 2017, Small.

[5]  Yinan Zhong,et al.  Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy. , 2014, Biomacromolecules.

[6]  J. Lewis,et al.  Synthesis of bombesin-functionalized iron oxide nanoparticles and their specific uptake in prostate cancer cells , 2010, Journal of nanoparticle research : an interdisciplinary forum for nanoscale science and technology.

[7]  J. F. Burrows,et al.  Targeting Siglecs with a sialic acid–decorated nanoparticle abrogates inflammation , 2015, Science Translational Medicine.

[8]  Peeyush N. Goel,et al.  Anti-neuropilin 1 antibody Fab′ fragment conjugated liposomal docetaxel for active targeting of tumours , 2014, Journal of drug targeting.

[9]  S. Nikfar,et al.  A Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal Cancer , 2015, Avicenna journal of medical biotechnology.

[10]  Christopher J. Scott,et al.  Conatumumab (AMG 655) coated nanoparticles for targeted pro-apoptotic drug delivery. , 2011, Biomaterials.

[11]  Sinyoung Jeong,et al.  Highly robust and optimized conjugation of antibodies to nanoparticles using quantitatively validated protocols. , 2017, Nanoscale.

[12]  K. Kiick,et al.  Tunable degradation of maleimide-thiol adducts in reducing environments. , 2011, Bioconjugate chemistry.

[13]  Ching-Yu Chen,et al.  Overcoming Trastuzumab Resistance in HER2-Overexpressing Breast Cancer Cells by Using a Novel Celecoxib-Derived Phosphoinositide-Dependent Kinase-1 Inhibitor , 2006, Molecular Pharmacology.

[14]  Mark E. B. Smith,et al.  Bromopyridazinedione-mediated protein and peptide bioconjugation† †Electronic supplementary information (ESI) available: Full experimental details and characterisation. See DOI: 10.1039/c1cc12807h Click here for additional data file. , 2011, Chemical communications.

[15]  J. Pinkas,et al.  Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates. , 2016, Bioconjugate chemistry.

[16]  S. Caddick,et al.  Site-selective multi-porphyrin attachment enables the formation of a next-generation antibody-based photodynamic therapeutic. , 2015, Chemical communications.

[17]  A. Tsourkas,et al.  An intein-mediated site-specific click conjugation strategy for improved tumor targeting of nanoparticle systems. , 2010, Small.

[18]  Enrique Miranda,et al.  A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy , 2015, Nature Communications.

[19]  R. Kontermann,et al.  Dual Targeting of Tumor Cells with Bispecific Single-Chain Fv-Immunoliposomes , 2012 .

[20]  Yin Ren,et al.  In vivo tumor cell targeting with "click" nanoparticles. , 2008, Bioconjugate chemistry.

[21]  M. Shoichet,et al.  Click chemistry functionalized polymeric nanoparticles target corneal epithelial cells through RGD-cell surface receptors. , 2009, Bioconjugate chemistry.

[22]  M. Pezzullo,et al.  Click Chemistry Immobilization of Antibodies on Polymer Coated Gold Nanoparticles. , 2016, Langmuir : the ACS journal of surfaces and colloids.

[23]  Antoine Maruani,et al.  Antibody fragments as nanoparticle targeting ligands: a step in the right direction , 2016, Chemical science.

[24]  Christopher J H Porter,et al.  Conjugation of 10 kDa Linear PEG onto Trastuzumab Fab' Is Sufficient to Significantly Enhance Lymphatic Exposure while Preserving in Vitro Biological Activity. , 2016, Molecular pharmaceutics.

[25]  T. Allen,et al.  Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[26]  K. Blumenthal,et al.  Nicotinamide adenine dinucleotide phosphate-specific glutamate dehydrogenase of Neurospora. I. Isolation, subunits, amino acid composition, sulfhydryl groups, and identification of a lysine residue reactive with pyridoxal phosphate and N-ethylmaleimide. , 1973, The Journal of biological chemistry.

[27]  Patrick Couvreur,et al.  Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery. , 2013, Chemical Society reviews.

[28]  Véronique Préat,et al.  To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[29]  Igor L. Medintz,et al.  Single domain antibody-quantum dot conjugates for ricin detection by both fluoroimmunoassay and surface plasmon resonance. , 2013, Analytica chimica acta.

[30]  S. Mitragotri,et al.  Nanoparticles in the clinic , 2016, Bioengineering & translational medicine.

[31]  Tim Beißbarth,et al.  mRNA Profiling Reveals Determinants of Trastuzumab Efficiency in HER2-Positive Breast Cancer , 2015, PloS one.

[32]  A. Tsourkas,et al.  Comparative Analysis of Nanoparticle-Antibody Conjugations: Carbodiimide Versus Click Chemistry , 2009, Molecular imaging.

[33]  M. Soussan,et al.  Carbodiimide versus click chemistry for nanoparticle surface functionalization: a comparative study for the elaboration of multimodal superparamagnetic nanoparticles targeting αvβ3 integrins. , 2013, Langmuir : the ACS journal of surfaces and colloids.

[34]  T. Pellegrino,et al.  Targeting FR-expressing cells in ovarian cancer with Fab-functionalized nanoparticles: a full study to provide the proof of principle from in vitro to in vivo. , 2015, Nanoscale.

[35]  Kristofer J. Thurecht,et al.  Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date , 2016, Pharmaceutical Research.

[36]  G. Zanetti,et al.  Identification of Lys116 as the target of N-ethylmaleimide inactivation of ferredoxin:NADP+ oxidoreductase. , 1991, European journal of biochemistry.

[37]  Omid C Farokhzad,et al.  Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. , 2012, Chemical Society reviews.

[38]  David S. Jones,et al.  Efficient drug delivery and induction of apoptosis in colorectal tumors using a death receptor 5-targeted nanomedicine. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[39]  G. Denardo,et al.  Development of multivalent radioimmunonanoparticles for cancer imaging and therapy. , 2008, Cancer biotherapy & radiopharmaceuticals.

[40]  E. K. Maloney,et al.  A novel pathway for maytansinoid release from thioether linked antibody-drug conjugates (ADCs) under oxidative conditions. , 2011, Chemical communications.

[41]  F. Bertucci,et al.  ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines , 2007, Oncogene.

[42]  Mark E. B. Smith,et al.  Pyridazinediones deliver potent, stable, targeted and efficacious antibody–drug conjugates (ADCs) with a controlled loading of 4 drugs per antibody , 2017 .

[43]  C. Grüttner,et al.  Comparison of Strain-Promoted Alkyne-Azide Cycloaddition With Established Methods for Conjugation of Biomolecules to Magnetic Nanoparticles , 2013, IEEE Transactions on Magnetics.

[44]  V. Chudasama,et al.  The Use of 3,6-Pyridazinediones in Organic Synthesis and Chemical Biology , 2016 .

[45]  Keith E Maier,et al.  Delivery of siRNAs to Dendritic Cells Using DEC205-Targeted Lipid Nanoparticles to Inhibit Immune Responses , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[46]  Carlos L. Arteaga,et al.  Treatment of HER2-positive breast cancer: current status and future perspectives , 2012, Nature Reviews Clinical Oncology.

[47]  Raoul Kopelman,et al.  Click conjugation of peptide to hydrogel nanoparticles for tumor-targeted drug delivery. , 2014, Biomacromolecules.

[48]  P. Kantoff,et al.  Cancer nanomedicine: progress, challenges and opportunities , 2016, Nature Reviews Cancer.

[49]  Xiaoyang Xu,et al.  Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. , 2014, Advanced drug delivery reviews.